Results 211 to 220 of about 877,569 (275)

A budding science of illegal markets. [PDF]

Proc Natl Acad Sci U S A
Caulkins JP.
europepmc   +1 more source

A sustainable business ecosystem: a case study demonstrating biochar's potential

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Juuso Kivijakola, Eemeli Erkheikki, Viljo Lukka, Pekka Tervonen, Harri Haapasalo   +4 more
wiley   +1 more source

Doctors paying forward. [PDF]

Lancet Reg Health Am
Barchas RE.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

From benefactor to outsider: conditional personhood and the withdrawal of recognition after sudden wealth in an unequal, collectivist context. [PDF]

Front Sociol
Sekaja L, Mabitsela-Siwela T, van der Merwe EP.   +2 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

How IoT Enables the Protective Action Decision Model (PADM) During a Wildfire Event. [PDF]

Risk Anal
Clark BY, Bashar S.
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Economic insecurity, access to menstrual materials, and sexual coercion: a qualitative study among adolescent schoolgirls in Ibadan, Nigeria. [PDF]

Reprod Health
Frost EL, Reed E, Goldenberg S, Bazzi AR, Fawole OI, Salawu MM, Okedare OO, L Kayser G.   +7 more
europepmc   +1 more source